Navigation Links
Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain
Date:12/3/2009

Nutra Pharma will be conducting a webinar on December 10, 2009, to discuss the Company’s over-the-counter and prescription treatments for chronic pain, Cobroxin and Nyloxin Rx.

Plantation, FL (Vocus) December 3, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company’s treatments for chronic pain.

“Over the past few months, we have been gaining traction in the pain market through the launch of our over-the-counter pain reliever, Cobroxin, and our recently introduced prescription pain reliever, Nyloxin Rx,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We would like to invite all of our shareholders and other interested parties to join us on this webinar so that we may explain our current progress and our short-term and long-term goals,” he added.

Registration is limited. To register for the upcoming webinar, visit http://tinyurl.com/NPHCwebinar.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
http://www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the upcoming webinar about the Company’s treatments for chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact:
Nutra Pharma Corp.
David Isserman
877-895-5647

# # #

Read the full story at http://www.prweb.com/releases/Nutra_Pharma/chronic_pain/prweb3292834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks
2. Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
3. Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
4. Vivakor Presents at Nutraceutical Event
5. Reportlinker Adds US World Nutraceutical Ingredients Industry
6. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
7. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
8. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
9. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
10. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
11. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu ... fully redesigned website, which launched October 17, 2016, features comprehensive information regarding a ... easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments for ...
(Date:12/7/2016)... ... 07, 2016 , ... The medical profession is well aware that heart attacks ... study analyzing heart attacks among 138,602 people recorded a 35% higher number of heart ... all agree of course–no time of year is a good time for a heart ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: an informative ... a one hour a week showing of hands. “The Road To Restoration” is the ... you are familiar with the brass ring that you could reach out for, and ...
(Date:12/7/2016)... ... 2016 , ... The Business Architecture Guild is ... on March 21-22, 2017. This premier event features business practitioners and experts from ... of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, and utilities. ...
(Date:12/6/2016)... ... December 06, 2016 , ... The International Vaccine ... a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will ... Korea for emergency deployment in the event of a future outbreak. , IVI ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Anaplastic Oligoastrocytoma - Pipeline Review, H2 ... Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma ... of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. ... when two types of cells in the brain, ... to form a mass. These brain cells are ...
(Date:12/6/2016)... -- Human Vaccines Market: Scope and Methodology ... wise analysis of the human vaccines market. Stakeholders ... products, raw material suppliers, vaccine processing companies, and ... The report provides qualitative and quantitative analysis of ... market dynamics, trends, product overview, and country-level market ...
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
Breaking Medicine Technology: